Skip to main content

Olema Pharmaceuticals

Olema Pharmaceuticals Inc is an American clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, prominently featuring its proprietary oral selective estrogen receptor degrader (SERD) candidate, palazestrant, designed for the treatment of estrogen receptor-positive (ER+) advanced breast cancer. The company conducts advanced clinical trials evaluating novel oncology therapeutics intended to overcome treatment resistance in metastatic breast cancer patients. Its core business operations encompass biopharmaceutical oncology research, drug discovery, clinical trial execution, and pharmaceutical development. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its ongoing operational activities through public equity offerings and strategic biopharmaceutical research collaborations. Olema Pharmaceuticals holds a pioneering market position in targeted breast cancer therapeutics. The company is headquartered in San Francisco, California, United States, and its common stock trades on the Nasdaq Global Select Market.

7 of the funds FundTelligence covers report a position in Olema Pharmaceuticals.

Legal name
Olema Pharmaceuticals Inc
Sector
Health Care
Country
United States
Funds holding it
7

Funds holding Olema Pharmaceuticals

Loading...